Poor
Not Aligned
Patient Risk:
High
Summary
Most claims in the provided list do not align with the supplied FDA label excerpt for SUBVENITE’s WARNING on serious skin rashes. Additionally, the drug/active ingredient mapping is incorrect in the label assessment content (shows lamotrigine while the provided 'Drug and active ingredient(s)' section states lamotrigine, conflicting with the evaluated excerpt context). No claims specifically described the boxed-warning risk factors/timing/instructions found in the excerpt; instead, many unrelated general levetiracetam/epilepsy statements appear, which are unsupported by the supplied label.
Category Scores
Accurate Statements
The exact approved indications for Subvenite depend on the country and the specific product format.
Not supported or contradicted by the provided WARNING/SERIOUS SKIN RASHES excerpts.
Unsupported Statements
"Subvenite" is a brand name for a medicine containing levetiracetam.
The provided label excerpts are for SUBVENITE and describe serious skin rashes due to SUBVENITE (lamotrigine per provided label context). The excerpt does not support levetiracetam.
Levetiracetam is an anti-seizure drug used to treat epilepsy.
Not supported by the supplied SUBVENITE serious skin rash excerpts.
Subvenite is prescribed to help control seizures in people with epilepsy.
The supplied excerpts are limited to WARNING/SERIOUS SKIN RASHES and do not state indications.
Subvenite is used for certain types of seizures in adults and children.
Not supported by the provided excerpts (which include population incidence data but not labeled indications).
Dosing of Subvenite depends on a person’s age.
The provided excerpts do not provide dosing-by-age statements.
Dosing of Subvenite depends on a person’s seizure type.
The provided excerpts do not link dosing to seizure type.
Dosing of Subvenite depends on a person’s kidney function.
The provided excerpts do not discuss kidney function dosing adjustments.
Dosing of Subvenite depends on the prescribed formulation (e.g., tablets vs. oral solution).
The provided excerpts do not discuss formulation-specific dosing.
Levetiracetam is typically taken twice daily.
Not supported by the provided SUBVENITE serious skin rash excerpts.
The dosing schedule of levetiracetam can vary.
Not supported by the provided SUBVENITE serious skin rash excerpts.
Common side effects reported with levetiracetam can include sleepiness or tiredness.
Not supported by the provided excerpts.
Common side effects reported with levetiracetam can include dizziness.
Not supported by the provided excerpts.
Common side effects reported with levetiracetam can include headache.
Not supported by the provided excerpts.
Common side effects reported with levetiracetam can include irritability or mood changes.
Not supported by the provided excerpts.
Serious reactions with levetiracetam are less common but can occur.
Not supported by the provided excerpts (which discuss serious skin rashes for SUBVENITE).
Stopping Subvenite suddenly can raise the risk of seizures returning or worsening.
The provided excerpts do not state anything about seizure recurrence/worsening with abrupt discontinuation.
Any change or discontinuation of Subvenite should be done through a clinician’s plan.
The provided excerpts instruct to discontinue SUBVENITE at first sign of rash unless clearly not drug-related, but do not support a general 'clinician's plan' phrasing.
A clinician’s discontinuation plan often involves gradual dose reduction.
The provided excerpts emphasize ordinary discontinuation at the first sign of rash; they do not describe gradual dose reduction.
People with kidney problems usually need dose adjustments with levetiracetam.
Not supported by the provided excerpts and also refers to levetiracetam.
Anyone taking other medicines should check for interaction considerations with a healthcare professional.
The provided excerpts only identify a specific risk factor (valproate coadministration) and do not support a general interaction instruction.
Levetiracetam is sold under multiple brand names in different countries.
Not supported by the provided excerpts.
“Subvenite” refers to a specific branded version of levetiracetam.
Conflicts with the supplied label context for SUBVENITE (serious skin rash warning content for SUBVENITE/lamotrigine).
Contradictions
High
AI Statement
"Subvenite" is a brand name for a medicine containing levetiracetam.
Label Reference
Boxed Warning (WARNING: SERIOUS SKIN RASHES) and Section 5.1 provided reference SUBVENITE and discuss lamotrigine-associated risk factors (e.g., HLA-B*1502 association with lamotrigine SJS/TEN).
High
AI Statement
“Subvenite” refers to a specific branded version of levetiracetam.
Label Reference
Same as above; the provided excerpt text indicates lamotrigine-associated HLA-B*1502/SJS-TEN risk, not levetiracetam.
Important Omissions
The response list does not mention key boxed-warning elements from the provided FDA excerpt: (1) incidence ranges (pediatric ~0.3%–0.8%, adults ~0.08%–0.3%), (2) timing (nearly all within 2–8 weeks), (3) specific risk factors (valproate coadministration, exceeding recommended initial dose and/or dose escalation, HLA-B*1502 allele, history of rash/allergy), and (4) instruction to ordinarily discontinue at first sign of rash unless clearly not drug-related.
Importance:
High
No contraindication information is included from the provided excerpt (contraindicated in patients with demonstrated hypersensitivity to SUBVENITE/ingredients, including rash/angioedema/acute urticaria/mucosal ulceration).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The evaluated claims misidentify the active ingredient/class (levetiracetam vs SUBVENITE/lamotrigine context) and fail to include the critical boxed-warning safety instructions and risk factors for serious skin rashes.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Numerous claims are unrelated to the supplied label excerpt and several directly conflict with the SUBVENITE-associated product identity (levetiracetam vs SUBVENITE/lamotrigine context). Critical boxed-warning content (risk factors, timing, and discontinue-at-first-sign instruction) is omitted.
Suggested Improvement
Replace levetiracetam-related statements with SUBVENITE-specific boxed-warning details from the provided excerpts, including incidence ranges, typical onset timing (2–8 weeks), risk factors (valproate coadministration, dose escalation/initial dose exceeding, HLA-B*1502, history of rash/allergy), and the instruction to ordinarily discontinue at the first sign of rash unless clearly not drug-related.